Page 167 - 2022_02-Haematologica-web

Prolonged maintenance with rituximab in indolent NHL
pared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective ran- domized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104 (10):3064-3071.
23. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non- Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295- 3301.
24. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized inter- group study. J Clin Oncol. 2010;28(17):2853- 2858.
25. Oh SY, Kim WS, Kim JS, et al. Phase II study of R-CVP followed by rituximab mainte- nance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Cancer Commun (Lond) 2019;39 (1):58.
26.Ferrario A, Pulsoni A, Olivero B, et al. Fludarabine, cyclophosphamide, and ritux- imab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation. Cancer. 2012;118(16):3954- 3961.
27. Bachy E, Seymour JF, Feugier P, et al.
Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol. 2019;37(31): 2815-2824.
28.Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analy- sis of randomized trials. J Natl Cancer Inst. 2011;103(23):1799-1806.
29. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lym- phoma. J Clin Oncol. 2007;25(5):579-586.
30. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognos- tic index. Blood. 2004;104(5):1258-1265.
31. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R- FCM) in patients with recurring and refrac- tory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108(13): 4003-4008.
32. Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follic- ular lymphoma receiving single-agent ritux- imab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28(29): 4480-4484.
33. Barta SK, Li H, Hochster HS, et al.
Randomized phase 3 study in low-grade lymphoma comparing maintenance anti- CD20 antibody with observation after induction therapy: a trial of the ECOG- ACRIN Cancer Research Group (E1496). Cancer. 2016;122(19):2996-3004.
34. Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus flu- darabine plus rituximab for patients with relapsed indolent and mantle-cell lym- phomas: a multicentre, randomised, open- label, non-inferiority phase 3 trial. Lancet Oncol. 2016;17(1):57-66.
35. Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014;17(7):459-468.
36. Rule S, Briones J, Smith R, et al. Preference for rituximab subcutaneous (SC) and intra- venous (IV) among patients with CD20+ non-Hodgkin's lymphoma (NHL) complet- ing the RASQ measure In randomized phase III studies Prefmab and Mabcute. Value Health. 2014;17(7):A537.
37. Sakai R, Ohmachi K, Sano F, et al. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lym- phoma: a multicenter phase II study. Ann Hematol. 2019;98(9):2131-2138.
38. Salar A, Avivi I, Bittner B, et al. Comparison of subcutaneous versus intravenous admin- istration of rituximab as maintenance treat- ment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014;32(17):1782-1791.
haematologica | 2022; 107(2)
509